




Advancing Academic Research

BIBLIOGRAPHY OF PUBLISHED PAPERS AND
PRESENTATIONS USING IQVIA INFORMATION



OCTOBER
2020

Introduction



IQVIA information is used extensively by researchers around the world to advance the understanding of Human Data Science— a discipline that advances human health by helping stakeholders throughout the healthcare ecosystem make more insightful, data-driven decisions. As a leading global information and technology services partner, we collaborate with academics and others whose research can be significantly advanced through access to IQVIA proprietary information.

This activity generates a significant number of peer-reviewed publications and conference presentations, covering a broad range of health care topics. The range of information accessed and used for research purposes is extensive. It includes summarized global and national prescription drug volume and sales information, provider-level prescription information, non-identified longitudinal patient data, provider profiles and organizational relationships, and commercial insurance medical and pharmacy claims information.

Data privacy is a priority at IQVIA. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that supports healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes.

This IQVIA bibliography provides a summary of research published from January 2019 through June 2020 that was undertaken by academic researchers who utilized IQVIA data assets.

To learn more specifics about IQVIA's data privacy policies

visit www.iqvia.com/about-us/privacy/privacy-policy and www.iqvia.com/about-us/privacy/privacy-shield-policy

It is organized in reverse chronological order by publication date and segmented into four themes:

- Understanding disease and treatment patterns
- Providing context for healthcare costs
- Assessing policy levers
- Advancing real world patient-level clinical evidence

Collectively, this research represents a substantial advancement in understanding the real world operation of our health system and is invaluable to multiple stakeholders. This bibliography has been produced as a public service without industry or government funding.

Find Out More

If you wish to receive future reports from the IQVIA Institute for Human Data Science or join our mailing list, visit iqviainstitute.org

MURRAY AITKEN


Executive Director

IQVIA Institute for Human Data Science

Table of contents



Understanding disease and treatment patterns	2
Providing context for healthcare costs	7
Assessing policy levers	10
Advancing real world patient-level clinical evidence	12
About the IQVIA Institute	17



Understanding disease and treatment patterns

As the number of new therapeutic treatment options for patients continues to climb, and new approaches to diagnostics and use of biomarkers are adopted, the complexity of clinical decision-making has increased for all stakeholders in healthcare. Understanding disease and treatment patterns contributes to better management of patients and disease, as well as the sustainability of healthcare systems. This recent research covers a large number of vital health issues, including the use of antibiotics, opioids, and oncologics, among others. All of these treatment areas require evidence-based research based on real-world data using non-identified granular data to elicit new and useful insights for clinicians, payers, policymakers, and patients.

Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users

BMC nephrology. 2020

Blankenburg M, Kovesdy CP, Fett AK, Griner RG, Gay A

Increased odds of ventricular arrhythmias associated with selective serotonin reuptake inhibitor use among the pediatric and young adult population: A case-control study

The Journal of Pediatrics. 2020

Czaja AS, Anderson HD, Ghosh D, Davidson J, Campbell JD, Valuck RJ

Variation in adult outpatient opioid prescription dispensing by age and sex—United States, 2008–2018

Morbidity and Mortality Weekly Report. 2020;69

Schieber LZ

Burn injury and incidence of psychiatric disorders: A retrospective cohort study of 18,198 patients from Germany

Burns. 2020 Jun 21

Bich CS, Kostev K, Baus A, Jacob L

Epidemiology of vernal keratoconjunctivitis in the United States: A claims data analysis

Investigative Ophthalmology & Visual Science. 2020

Jun 10;61(7):4592

Babineaux S, Blalock S, Katz J

The impact of influenza vaccination on antibiotic use in the United States, 2010-2017

Open Forum Infectious Diseases 2020 Jun 6

Klein EY, Schueller E, Tseng KK, Morgan DJ, Laxminarayan R, Nandi A

Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists, and others: Trends in buprenorphine treatment by prescriber specialty-primary care providers, psychiatrists, and addiction medicine specialists

Health Affairs. 2020 Jun 1;39(6):984-92

Olfson M, Zhang V, Schoenbaum M, King M

The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsistent

Alimentary Pharmacology & Therapeutics. 2020

May;51(10):958-67

Forsmark CE, Tang G, Xu H, Tuft M, Hughes SJ, Yadav D

Understanding doctor decision making: The case of depression treatment

Econometrica. 2020 May;88(3):847-78

Currie JM, MacLeod WB

Increased prevalence of depression, anxiety, and adjustment and somatoform disorders in transsexual individuals

Journal of Affective Disorders. 2020 May 25

Konrad M, Kostev K

Association between thyroid gland diseases and breast cancer: a case-control study

Breast Cancer Research and Treatment. 2020 May 18

Bach L, Kostev K, Schiffmann L, Kader M

Incidence of pharyngitis, sinusitis, acute otitis media, and outpatient antibiotic prescribing preventable by vaccination against group A Streptococcus in the United States

Clinical Infectious Diseases. 2020 May 6

Lewnard JA, King LM, Fleming-Dutra KE, Link-Gelles R, Van Beneden CA

UNDERSTANDING DISEASE AND TREATMENT PATTERNS

Evaluation of the reported rates of hypersensitivity reactions associated with iron dextran and ferric carboxymaltose based on global data from VigiBase™ and IQVIA™ MIDAS® over a ten-year period from 2008 to 2017

Expert Review of Hematology. 2020 May 3;13(5):557-64
Durup D, Schaffalitzky de Muckadell P, Strom CC

Drug treatment for patients with bipolar disorders in psychiatric practices in Germany in 2009 and 2018

Psychiatry Research. 2020 May 1:112965
Bohlken J, Bauer M, Kostev K

Place, poverty and prescriptions: a cross-sectional study using Area Deprivation Index to assess opioid use and drug-poisoning mortality in the USA from 2012 to 2017

BMJ open. 2020 May 1;10(5):e035376
Kurani S, McCoy RG, Inselman J, Jeffery MM, Chawla S, Rutten LJ, Giblon R, Shah ND

Influence of chemotherapy and endocrine treatment on fractures in postmenopausal women with breast cancer—a retrospective cohort study

Journal of Bone Oncology. 2020 Apr 24:100292
Stumpf U, Kostev K, Siebenbürger G, Böcker W, Hadji P

Patterns of lisdexamfetamine dimesylate use in children, adolescents, and adults with attention-deficit/hyperactivity disorder in Europe

Journal of Child and Adolescent Psychopharmacology. 2020 Apr 21
Siffel C, Page M, Maxwell T, Thun B, Kolb N, Rosenlund M, von Bredow D, Keja J

A survey of physician experience and treatment satisfaction using fast-acting insulin aspart in people with type 1 or type 2 diabetes

Postgraduate Medicine. 2020 Apr 20:1-8
Baru A, Amir S, Ekelund M, Montagnoli R, Da Rocha Fernandes JD

Incidence of and factors associated with manic episodes and bipolar disorder in the decade following depression onset in Germany

Journal of Affective Disorders. 2020 Apr 1;266:534-9
Jacob L, Bohlken J, Kostev K

Buprenorphine dispensing in an epicenter of the US opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky

International Journal of Drug Policy. 2020 Mar 26:102701
Cooper HL, Cloud DH, Freeman PR, Fadanelli M, Green T, Van Meter C, Beane S, Ibragimov U, Young AM

Cultural drivers of antibiotic consumption in high-income countries: A global ecological analysis

Microbial Drug Resistance. 2020 Mar 17
Kenyon C, Manoharan-Basil SS

Population-level antimicrobial consumption is associated with decreased antimicrobial susceptibility in *Neisseria gonorrhoeae* in 24 European countries: An ecological analysis

The Journal of infectious diseases. 2020 Mar 16;221(7):1107-16
Kenyon C, Buyze J, Spiteri G, Cole MJ, Unemo M

Treatment patterns for chronic comorbid conditions in patients with cancer using a large-scale observational data network

JCO Clinical Cancer Informatics. 2020 Mar;4:171-83
Chen R, Ryan P, Natarajan K, Falconer T, Crew KD, Reich CG, Vashisht R, Randhawa G, Shah NH, Hripcsak G

Use of monoclonal antibodies for asthma in the United States, 2003-2019

Journal of Allergy and Clinical Immunology. 2020 Feb 1;145(2):AB23
Akenroye A, Heyward J, Alexander C, Keet C

The role of unit-dose child-resistant packaging in unintentional childhood exposures to buprenorphine-naloxone tablets

Drug safety. 2020 Feb;43(2):189-91
Hampp C, Lovegrove MC, Budnitz DS, Mathew J, Ho A, McAninch J

Incidence of fractures in patients with type 1 diabetes mellitus—a retrospective study with 4420 patients

Osteoporosis international. 2020 Feb 23:1-8
Stumpf U, Hadji P, van den Boom L, Böcker W, Kostev K

UNDERSTANDING DISEASE AND TREATMENT PATTERNS

Evaluation of the clinical and economic burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the United States

Advances in therapy. 2020 Feb 1;37(2):869-82
Ali SN, Dang-Tan T, Valentine WJ, Hansen BB

Adherence to neuroleptic treatment in psychiatric practices: A retrospective study of 55 practices with more than 5000 bipolar and schizophrenic patients in Germany

Psychiatry Research. 2020 Feb 1;284:112758
Bohlken J, Konrad M, Kostev K

Emergence and burden of antibiotic drug resistance: An endogenous cycle

Current Science. 2020 Jan 25;118(2):189
Malik B, Bhattacharyya S

Trends in buprenorphine treatment in the United States, 2009-2018

Jama. 2020 Jan 21;323(3):276-7
Olfson M, Zhang VS, Schoenbaum M, King M

Antiretroviral therapy adherence among treatment-naïve HIV-infected patients

Aids. 2020 Jan 1;34(1):127-37
Chakraborty A, Qato DM, Awadalla SS, Hershov RC, Dworkin MS

Trends in opioid prescribing among hemodialysis patients, 2007-2014

American Journal of Nephrology. 2019;49(1):20-31
Daubresse M, Alexander GC, Crews DC, Segev DL, McAdams-DeMarco MA

Local exposure to school shootings and youth antidepressant use

National Bureau of Economic Research; 2019 Dec 12
Rossin-Slater M, Schnell M, Schwandt H, Trejo S, Uniat L

Opioid prescription rates and risk for substantiated child abuse and neglect: a Bayesian spatiotemporal analysis

Drug and alcohol dependence. 2019 Dec 1;205:107623
Morris MC, Marco M, Bailey B, Ruiz E, Im W, Goodin B

The pharmacoepidemiology of psychotropic medication use in Canadian children from 2012 to 2016

Journal of Child and Adolescent Psychopharmacology. 2019 Dec 1;29(10):740-5
Pringsheim T, Stewart DG, Chan P, Tehrani A, Patten SB

Outpatient antibiotic prescription rate and pattern in the private sector in India: Evidence from medical audit data

PloS one. 2019 Nov 13;14(11):e0224848
Farooqui HH, Mehta A, Selvaraj S

Adaptation of the WHO Essential Medicines List for national antibiotic stewardship policy in England: being AWaRe

Journal of Antimicrobial Chemotherapy. 2019 Nov 1;74(11):3384-9
Budd E, Cramp E, Sharland M, Hand K, Howard P, Wilson P, Wilcox M, Muller-Pebody B, Hopkins S

Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study

Seminars in arthritis and rheumatism 2019 Oct 1 (Vol. 49, No. 2, pp. 222-228)
Kim SC, Pawar A, Desai RJ, Solomon DH, Gale S, Bao M, Sarsour K, Schneeweiss S

An approach for using in vitro and in silico data to identify pharmaceuticals with potential (anti-)estrogenic activity in aquatic vertebrates at environmentally relevant concentrations

Environmental toxicology and chemistry. 2019 Oct;38(10):2154-68
Pinto CL, Bloom RA, Laurenson JP

National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997-2017

Pharmacoepidemiology and drug safety. 2019 Sep;28(9):1246-50
Su ZT, Segal JB, Lanzkron S, Ogunsile FJ

Impact of medical marijuana legalization on opioid use, chronic opioid use, and high-risk opioid use

Journal of general internal medicine. 2019 Aug 15;34(8):1419-26
Shah A, Hayes CJ, Lakkad M, Martin BC

UNDERSTANDING DISEASE AND TREATMENT PATTERNS

Outpatient antibiotic prescribing in the United States: Are pediatricians leading the way?

Clinical Infectious Diseases. Accessed August 5, 2019
Gerber JS

Drug utilization patterns of flupirtine following implementation of risk minimization measures in Germany

Current medical research and opinion. 2019 Aug 3;35(8):1397-403
Kaplan S, Ehlken B, Hamann X

National opioid prescribing trends in emergency departments by provider type: 2005–2015

The American journal of emergency medicine. 2019 Aug 1;37(8):1439-45
Yang BK, Storr CL, Trinkoff AM, Sohn M, Idzik SK, McKinnon M

Association between trends in county-level opioid prescribing and reported rates of gonorrhea cases in the United States

Annals of epidemiology. 2019 Aug 1;36:26-32
Abara WE, Hong J, Dorji T, Bohm MK, Weston EJ, Bernstein KT, Kirkcaldy RD

The risk of varenicline-induced seizure among those who have attempted to quit smoking using pharmacotherapy

Epilepsy & Behavior. 2019 Aug 1;97:169-73
Chopra DA, Shah AB, Vadhariya AH, Painter JT

Population-level macrolide consumption is associated with clarithromycin resistance in *Helicobacter pylori*: An ecological analysis

International Journal of Infectious Diseases. 2019 Aug 1;85:67-9
Kenyon C

Where will non-Vitamin K oral anticoagulants stand beyond being standard of care in anticoagulation therapy?

International Journal of the Cardiovascular Academy. 2019 Jul 1;5(3):75
Ergene O

'Eyes In The Home': ACOs use home visits to improve care management, identify needs, and reduce hospital use

Health Affairs. 2019 Jun 1;38(6):1021-7
Fraze TK, Beidler LB, Briggs AD, Colla CH

Comparative human factors evaluation of two nasal naloxone administration devices: NARCAN® nasal spray and naloxone prefilled syringe with nasal atomizer

Pain and therapy. 2019 Jun 1;8(1):89-98
Tippey KG, Yovanoff M, McGrath LS, Sneeringer P

Comparison of opioid prescribing by dentists in the United States and England

JAMA Network Open. 2019 May 3;2(5)
Suda KJ, Durkin MJ, Calip GS, Gellad WF, Kim H, Lockhart PB, Rowan SA, Thornhill MH

Digoxin use and associated adverse events among older adults

The American Journal of Medicine. 2019 May 8
Angraal S, Nuti SV, Masoudi FA, Freeman JV, Murugiah K, Shah ND, Desai NR, Ranasinghe I, Wang Y, Krumholz HM

Claims for contraceptive services among young women filling chronic opioid prescriptions

Contraception. 2019 May 1;99(5):296-9
Ray-Griffith SL, Chopra D, Stowe ZN, Martin B

Association between pharmacy closures and adherence to cardiovascular medications among older US adults

JAMA Network Open. 2019 Apr 5;2(4)
Qato DM, Alexander GC, Chakraborty A, Guadamuz JS, Jackson JW

Outpatient antibiotic prescribing rate declines by 5% from 2011 to 2016

Infectious Diseases in Children. 2019 Apr 1;32(4):21
Bortz K

Changes in outpatient antibiotic utilization, 2000–2016: More people are receiving fewer antibiotics

Infection Control & Hospital Epidemiology. 2019 Mar;40(3):372-4
Cocoros NM, Ochoa A, Klompas M

UNDERSTANDING DISEASE AND TREATMENT PATTERNS

Changes in US outpatient antibiotic prescriptions from 2011–2016

Clinical Infectious Diseases. 2019 Mar 16
King LM, Bartoces M, Fleming-Dutra KE, Roberts RM, Hicks LA

Global monitoring of antimicrobial resistance based on metagenomics analyses of urban sewage

Nature communications. 2019 Mar 8;10(1):1-2
Hendriksen RS, Munk P, Njage P, Van Bunnik B, McNally L, Lukjancenko O, Röder T, Nieuwenhuijse D, Pedersen SK, Kjeldgaard J, Kaas RS

Persistence with biological drugs in patients treated in rheumatology practices in Germany

Rheumatology international. 2019 Mar 7;39(3):525-31
Jacob L, Chevalier T, Kostev K

Trends and patterns of geographic variation in opioid prescribing practices by state, United States, 2006-2017

JAMA Network Open. 2019 Mar 1;2(3)
Schieber LZ, Guy GP, Seth P, Young R, Mattson CL, Mikosz CA, Schieber RA

Oral fluoroquinolone prescribing to children in the United States from 2006 to 2015

The Pediatric Infectious Disease Journal 2019 Mar 1;38(3):268-70
Etminan M, Guo MY, Carleton B

Tumor necrosis factor inhibitor therapy and the risk for depression among working-age adults with rheumatoid arthritis

American health & drug benefits. 2019 Feb;12(1):30
Deb A, Dwibedi N, LeMasters T, Hornsby JA, Wei W, Sambamoorthi U

Assessment of use of combined dextromethorphan and quinidine in patients with dementia or parkinson disease after US Food and Drug Administration approval for pseudobulbar affect

JAMA internal medicine. 2019 Feb 1;179(2):224-30
Fralick M, Sacks CA, Kesselheim AS

Ingestion of over-the-counter liquid medications: Emergency department visits by children aged less than 6 Years, 2012–2015

American Journal of Preventive Medicine. 2019 Feb 1;56(2):288-92
Lovegrove MC, Weidle NJ, Budnitz DS

Gastroschisis trends and ecologic link to opioid prescription rates—United States, 2006–2015

Morbidity and Mortality Weekly Report. 2019 Jan 18;68(2):31
Short TD, Stallings EB, Isenburg J, O'Leary LA, Yazdy MM, Bohm MK, Ethen M, Chen X, Tran T, Fox DJ, Fornoff J

Enduring clinical value of Copaxone® (glatiramer acetate) in multiple sclerosis after 20 years of use

Multiple sclerosis international. 2019 Jan 15;2019
Wynn DR

Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries

The Lancet Infectious Diseases. 2019 Jan 1;19(1):67-7
Hsia Y, Sharland M, Jackson C, Wong IC, Magrini N, Bielicki JA

Management and clinical practice of multiple face and scalp actinic keratosis in France

Journal of market access & health policy. 2019 Jan 1;7(1):1605787
Savary J, Tine MC, Weber AC, Dorey J

A population-based, case-control evaluation of the association between hormonal contraceptives and idiopathic intracranial hypertension.

American journal of ophthalmology. 2019 Jan 1;197:74-9
Kilgore KP, Lee MS, Leavitt JA, Frank RD, McClelland CM, Chen JJ

Cardiovascular safety of concomitant use of atypical antipsychotics and long-acting stimulants in children and adolescents with ADHD

Journal of Attention Disorders. 2019 Jan;23(2):163-72
Bali V, Kamble PS, Aparasu RR

The association between gabapentin and suicidality in bipolar patients

International Clinical Psychopharmacology 2019 Jan 1;34(1):27-32
Leith WM, Lambert WE, Boehnlein JK, Freeman MD

Antimuscarinic use and discontinuation in an older adult population

Archives of gerontology and geriatrics. 2019 Jan 1;80:1-1
Vouri SM, Schootman M, Strobe SA, Xian H, Olsen MA

— Providing context for healthcare costs

Healthcare cost dynamics attract heightened attention each year as many – though not all – costs climb. Understanding drivers of costs – and savings – and their variability across patients, healthcare settings, and countries requires a combination of rigorous economic, clinical and analytical knowledge and skills applied to real-world cost and utilization data. These research efforts contribute to advancing the understanding of healthcare costs by providing context and clarity to this complex issue. Much of the focus is on pharmaceutical costs and the extent to which they are drivers of overall healthcare expenditure, as well as providing savings opportunities from generics, biosimilars and offset healthcare costs.

Uptake of biosimilar infliximab in the UK, France, Japan, and Korea: Budget savings or market expansion across countries?

Frontiers in Pharmacology. 2020;11

Kim Y, Kwon HY, Godman B, Moorkens E, Simoens S, Bae S

Comparative clinical and economic outcomes associated with warfarin versus apixaban in the treatment of patients with venous thromboembolism in a large US commercial claims database

Journal of Managed Care & Specialty Pharmacy. 2020;1-4

Guo JD, Rajpura J, Hlavacek P, Keshishian A, Sah J, Delinger R, Mu Q, Mardekian J, Russ C, Okano GJ, Rosenblatt L

Evaluating the long-term cost-effectiveness of once-weekly semaglutide versus once-daily liraglutide for the treatment of type 2 diabetes in the UK

Advances in therapy. 2020;37(5):2427

Johansen P, Chubb B, Hunt B, Malkin SJ, Sandberg A, Capehorn M

Market exclusivity for drugs with multiple orphan approvals (1983–2017) and associated budget impact in the US

PharmacoEconomics. 2020 Jun 12;1-7

Padula WV, Parasrampur S, Socal MP, Conti RM, Anderson GF

Healthcare resource utilization and direct medical costs associated with index and recurrent *Clostridioides difficile* infection: a real-world data analysis

Journal of Medical Economics. 2020 Jun 2;23(6):603-9

Feuerstadt P, Stong L, Dahdal DN, Sacks N, Lang K, Nelson WW

Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: A cross-sectional study

BMJ Open. 2020 Jun 1;10(6):e038863

Moore TJ, Heyward J, Anderson G, Alexander GC

How protected classes in Medicare Part D influence US drug sales, utilization, and price

Health Economics. 2020 May;29(5):608-23

Yarbrough CR

National trends in prescription drug expenditures and projections for 2020

American Journal of Health-System Pharmacy. 2020 May 15

Tichy EM, Schumock GT, Hoffman JM, Suda KJ, Rim MH, Tadrous M, Stubbings J, Cuellar S, Clark JS, Wiest MD, Matusiak LM

Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US

Social Science & Medicine. 2020 May 13;113042

Salas-Vega S, Shearer E, Mossialos E

A national survey of the frequency of drug company detailing visits and free sample closets in practices delivering primary care

JAMA Internal Medicine. 2020 Apr 1;180(4):592-5

King AC, Schwartz LM, Woloshin S

Economic and clinical burden of acute myeloid leukemia episodes of care in the United States: A retrospective analysis of a commercial payer database

Journal of Managed Care & Specialty Pharmacy. 2020 Apr;1-1

Pandya BJ, Chen CC, Medeiros BC, McGuinness CB, Wilson SD, Walsh EH, Wade RL

PROVIDING CONTEXT FOR HEALTHCARE COSTS

Economic burden of bronchiolitis obliterans syndrome (BOS) in lung transplant patients

The Journal of Heart and Lung Transplantation. 2020 Apr 1;39(4):S364-5
Sacks NC, Healey B, Cyr PL, Henig NR, Huang HJ

The cost of cancer in Europe 2018

European Journal of Cancer. 2020 Apr 1;129:41-9
Hofmarcher T, Lindgren P, Wilking N, Jönsson B

Cost per episode of care with collagenase clostridium histolyticum versus fasciectomy for Dupuytren contracture: a real-world claims database analysis

Journal of Hand Surgery Global Online. 2019 Apr 1;1(2):57-64
Camper SB, Divino V, Hurley D, DeKoven M

Estimated costs of pivotal trials for US Food and Drug Administration–approved cancer drugs, 2015–2017

Clinical Trials. 2020 Apr;17(2):119-25
Hsiue EH, Moore TJ, Alexander GC

Estimating the impact of Food and Drug Administration’s Unapproved Drug Initiative on drug prices and sales

Therapeutic innovation & regulatory science. 2020 Mar;54(2):424-30
Sharma D, Schumock GT, Saffore CD, Edwards SA, Walton SM

Estimation of the incremental cumulative cost of HIV compared with a non-HIV population

PharmacoEconomics-Open. 2020 Mar 26:1-0
Cohen JP, Beaubrun A, Ding Y, Wade RL, Hines DM

Four facts concerning competition in US generic prescription drug markets

International Journal of the Economics of Business. 2020 Jan 2;27(1):27-48
Conti RM, Berndt ER

Do mergers and acquisitions improve firms’ financial performance? The case of the US generic drug industry

Managerial and Decision Economics. 2020 Jan;41(1):10-24
Trujillo AJ, Garcia-Morales EE, Kabarriti G, Anderson G

Economic burden of spinal muscular atrophy in the United States: A contemporary assessment

Journal of Medical Economics. 2020 Jan 2;23(1):70-9
Droege M, Sproule D, Arjunji R, Gauthier-Loiselle M, Cloutier M, Dabbous O

Abatacept: from a budget impact model to cost-effectiveness analysis–data from RCT and real life

ClinicoEconomics and outcomes research: CEOR. 2019;11:405
Benucci M, Damiani A, Manfredi M, Infantino M, Grossi V, Gobbi FL

Health resource utilization and costs associated with the use of obinutuzumab-based regimens are similar to rituximab-based regimens for the first-line treatment of follicular lymphoma

Blood 134 (Supplement_1): 4721–4721 2019
To TM, Dawson KL, Masaquel AS, Seetasith A

Federal government-interest patent disclosures for recent top-selling drugs

Journal of medical economics. 2019 Dec 2;22(12):1261-7
Long G

Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis

Cost Effectiveness and Resource Allocation. 2019 Dec;17(1):13
Lau E, Salem A, Chan JC, So WY, Kong A, Lamotte M, Luk A

An analysis of orphan medicine expenditure in Europe: Is it sustainable?

Orphanet Journal of Rare Diseases. 2019 Dec 1;14(1):287
Mestre-Ferrandiz J, Palaska C, Kelly T, Hutchings A, Parnaby A

Association between physician adoption of a new oral anti-diabetic medication and Medicare and Medicaid drug spending

BMC health services research. 2019 Dec;19(1):1-1
Metes ID, Xue L, Chang CC, Huskamp HA, Gellad WF, Lo-Ciganic WH, Choudhry NK, Richards-Shubik S, Guclu H, Donohue JM

Tuberculosis treatment in the private healthcare sector in India: An analysis of recent trends and volumes using drug sales data

BMC Infectious Diseases. 2019 Dec 1;19(1):539
Arinaminpathy N, Batra D, Maheshwari N, Swaroop K, Sharma L, Sachdeva KS, Khaparde S, Rao R, Gupta D, Vadera B, Nair SA

PROVIDING CONTEXT FOR HEALTHCARE COSTS

Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs

PloS one. 2019 Nov 12;14(11):e0225109

Murimi-Worstell IB, Ballreich JM, Seamans MJ, Alexander GC

Differences in patient demographics and healthcare costs of patients with PIDD receiving intravenous or subcutaneous immunoglobulin therapies in the United States

American Health & Drug Benefits. 2019 Oct;12(6):294

Runken MC, Noone JM, Blanchette CM, Zacherle E, Howden R

Modeling the potential impact of abuse-deterrent opioids on medical resource utilization

Journal of medical economics. 2019 Oct 3;22(10):1073-9

Yenikomshian MA, White AG, Carson ME, Jia ZB, Mendoza MR, Roland CL

Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone

Journal of medical economics. 2019 Aug 3;22(8):818-29

Hagiwara M, Panjabi S, Sharma A, Delea TE

National trends in prescription drug expenditures and projections for 2019

American Journal of Health-System Pharmacy. 2019

Aug 1;76(15):1105-21

Schumock GT, Stubbings J, Hoffman JM, Wiest MD, Suda KJ, Rim MH, Tadrous M, Tichy EM, Cuellar S, Clark JS, Matusiak LM

Complex cost issues in treating dermatophytoses in India—"It All Builds Up"

Indian dermatology online journal. 2019 Jul;10(4):441

Verma SB

Effect of weight change on economic outcomes among persons with type 2 diabetes mellitus in the United States: Beyond glycemic control

Journal of Managed Care & Specialty Pharmacy. 2019

Jun;25(6):658-68

Karkare S, Fridman M, Dang-Tan T, Lu J, Smolarz BG, DeKoven M, Iyer NN

HIV-HCV co-infection substantial burden in the US

PharmacoEconomics & Outcomes News. 2019 Jun

Mattingly TJ

Economic value of a therapeutic chagas vaccine for indeterminate and chagasic cardiomyopathy patients

Vaccine. 2019 Jun 19;37(28):3704-14

Bartsch SM, Bottazzi ME, Asti L, Strych U, Meymandi S, Falcón-Lezama JA, Randall S, Hotez PJ, Lee BY

Federal government-interest patent disclosures for recent top-selling drugs

Journal of Medical Economics. 2019 Jun 13

Long G

Analysis of human immunodeficiency virus in a commercially insured hepatitis c virus population

Infectious Diseases and Therapy. 2019 Jun 1;8(2):219-28

Mattingly TJ, Pandit NS, Onukwugha E

The association between the severity of chronic kidney disease and medical costs among patients with type 2 diabetes

Journal of Medical Economics. 2019 May 4;22(5):447-54

Lage MJ, Boye KS, Bae JP, Wu J, Mody R, Botros FT

The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients

Journal of Medical Economics. 2019 Apr 3;22(4):350-8

Shahabi A, Shafrin J, Zhao L, Green S, Curtice T, Marshall A, Paul D

Exploring the use of machine learning for risk adjustment: A comparison of standard and penalized linear regression models in predicting health care costs in older adults

PloS One. 2019 Mar 6;14(3)

Kan HJ, Kharrazi H, Chang HY, Bodycombe D, Lemke K, Weiner JP

The contribution of new product entry versus existing product inflation in the rising costs of drugs

Health Affairs. 2019 Jan 1;38(1):76-83

Hernandez I, Good CB, Cutler DM, Gellad WF, Parekh N, Shrank WH

Assessing policy levers

Changes in public health priorities, budgets, and patient needs contribute to evolving policies related to the governance and operation of healthcare systems and directly affect all healthcare stakeholders. The policy goals, elements and approach to implementation vary widely. So too, do the measures of intended – and unintended – consequences. Applying evidence-based assessments to policy levers bring knowledge and insight that help shape policy modifications and strengthen future policy decision-making. Among the recent research undertaken in this area are studies of policies related to prescription opioid use, environmental risks associated with active pharmaceutical ingredients, the use of generics and biosimilars, and adoption of health information technologies. This collective body of research, if fully embraced and learnings applied, can contribute to improved policy development across a broad range of health areas.

Spillover effects of state Medicaid antipsychotic prior authorization policies in US commercially insured youth

Pharmacoepidemiology and Drug Safety. 2020 Jun 18
Spence OM, Reeves G, DosReis S

What is a freestanding emergency department? Definitions differ across major United States data sources

Western Journal of Emergency Medicine. 2020
May;21(3):660
Herscovici DM, Boggs KM, Sullivan AF, Camargo Jr CA

Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: A cross-sectional study

Drug and Alcohol Dependence. 2020 May 25:108083
Roehler DR, Guy Jr GP, Jones CM

The changing health insurance coverage landscape in the United States

American Society of Clinical Oncology Educational Book. 2020 May 1;40:e264-74
Yabroff KR, Valdez S, Jacobson M, Han X, Fendrick AM

Association of organizational factors and physician practices' participation in alternative payment models

JAMA network open. 2020 Apr 1;3(4):e202019
Ouayogodé MH, Frazee T, Rich EC, Colla CH

Association between state Medicaid expansion status and naloxone prescription dispensing

Health Services Research. 2020 Apr;55(2):239-48
Sohn M, Talbert JC, Delcher C, Hankosky ER, Lofwall MR, Freeman PR

Changes in emergency department visits for zolpidem-attributed adverse drug reactions after FDA Drug Safety Communications

Pharmacoepidemiology and Drug Safety. 2020
Mar;29(3):352-6
Geller AI, Zhou EH, Budnitz DS, Lovegrove MC, Dal Pan GJ

Analysis of a high-prescribing state's 2016 outpatient antibiotic prescriptions: Implications for outpatient antimicrobial stewardship interventions

Infection Control & Hospital Epidemiology. 2020
Feb;41(2):135-42
Staub MB, Ouedraogo Y, Evans CD, Katz SE, Talley PP, Kainer MA, Nelson GE

Effective market exclusivity of new molecular entities for rare and non-rare diseases

Pharmaceutical Medicine. 2020 Feb;34(1):19-29
Kerr KW, Glos LJ

Does the use of health technology assessment have an impact on the utilisation of health care resources? Evidence from two European countries

The European Journal of Health Economics. 2020 Feb
5:1-4
Corbacho B, Drummond M, Santos R, Jones E, Borràs JM, Mestre-Ferrandiz J, Espín J, Henry N, Prat A

ASSESSING POLICY LEVERS

Playing both sides: Branded sales, generic drugs, and antitrust policy

Hastings LJ. 2019;71:307

Carrier MA, Lemley MA, Miller S

Just what the nurse practitioner ordered: Independent prescriptive authority and population mental health

Journal of Health Economics. 2019

Alexander D, Schnell M

Opioid and benzodiazepine coprescribing in the United States before and after US Food and Drug Administration boxed warning

JAMA psychiatry. 2019 Nov 1;76(11):1208-10

Zhang VS, Olfson M, King M

Environmental risk assessment for the active pharmaceutical ingredient mycophenolic acid in European surface waters

Environmental toxicology and chemistry. 2019

Oct;38(10):2259-78

Straub JO, Oldenkamp R, Pfister T, Häner A

Prevalence of screening for food insecurity, housing instability, utility needs, transportation needs, and interpersonal violence by US physician practices and hospitals

JAMA network open. 2019 Sep 4;2(9):e1911514-

Fraze TK, Brewster AL, Lewis VA, Beidler LB, Murray GF, Colla CH

Different policy measures and practices between Swedish counties influence market dynamics: Part 1—biosimilar and originator infliximab in the hospital setting

BioDrugs. 2019 Jun 1;33(3):285-97

Moorkens E, Simoens S, Troein P, Declerck P, Vulto AG, Huys I

Association of naloxone coprescription laws with naloxone prescription dispensing in the United States

JAMA Network Open. 2019 Jun 5;2(6)

Sohn M, Talbert JC, Huang Z, Lofwall MR, Freeman PR

Globalization of clinical trials: Variation in estimated regional costs of pivotal trials, 2015–2016

Clinical Trials. 2019 Jun 1

Qiao Y, Alexander GC, Moore TJ

Association of criminal statutes for opioid use disorder with prevalence and treatment among pregnant women with commercial insurance in the United States

JAMA Network Open. 2019 Mar 1;2(3)

Gressler LE, Shah S, Shaya FT

Organizational influences on health care system adoption and use of advanced health information technology capabilities

The American Journal of Managed Care. 2019 Jan 1;25(1):e21

Norton PT, Rodriguez HP, Shortell SM, Lewis VA

Using trajectory models to assess the effect of hydrocodone upscheduling among chronic hydrocodone users

Pharmacoepidemiology and Drug Safety. 2019

Jan;28(1):70-9

Murimi IB, Chang HY, Bicket M, Jones CM, Alexander GC

— Advancing real world patient-level clinical evidence

Variability in clinical care and use of alternative treatment pathways contributes in some cases to sub-optimal patient outcomes. Understanding the drivers of this variability and how it affects patient sub-populations is critical to advancing care. The growing availability of real world patient-level data enables this research to advance and bring greater clarity to defining optimal care. It can also be the basis for predictive medicine and for artificial intelligence and machine learning applications. Researchers have been advancing their understanding across many disease areas and treatment settings, using a variety of electronic health record, claims and other data sources. This collection of research also reinforces the diversity of clinical care issues that require new understanding and can benefit from patient-level clinical evidence.

National Comprehensive Cancer Network (NCCN) category I/FDA-approved metastatic pancreatic adenocarcinoma (mPDAC) treatments in commercially insured patients: An analysis of inpatient (IP) and emergency room (ER) admissions

Cockrum P, Surinach A, Arndorfer S, Koeller JM, Kim GP
Journal of Clinical Oncology 2020 Vol 38 Issue 15

Real-world clinical and economic burden associated with hospitalization in metastatic triple-negative (ER-/PR-/HER2-) breast cancer

Journal of Clinical Oncology 2020

Tan A, Han X, Near A, Tse J, Preger L

Changes in the utilization of blood glucose test strips among patients using intermittent-scanning continuous glucose monitoring in Germany

Diabetes Obesity and Metabolism. 2020 Jun;22(6):922-8
van den Boom L, Kostev K

Incidence, risk factors, and outcomes of pouchitis and pouch-related complications in patients with ulcerative colitis

Clinical Gastroenterology and Hepatology. 2020 Jun 22

Barnes EL, Herfarth HH, Kappelman MD, Zhang X, Lightner A, Long MD, Sandler RS

Return-to-function following treatment of dupuytren contracture with collagenase clostridium histolyticum versus fasciectomy

HAND. 2020 Jun 7:1558944720919923

Divino VM, DeKoven M, Hurley D

Prevalence of insulin as a first-line therapy and associated factors in people with type 2 diabetes in German primary care practices

Diabetic Medicine. 2020 Jun 7

van den Boom L, Kaiser M, Kostev K

Real-world treatment patterns, adverse events, resource use, and costs among commercially insured, younger patients with chronic lymphocytic leukemia in the USA: A retrospective cohortsStudy

Advances in therapy. 2020 May 12

Kabadi SM, Near A, Wada K, Burudpakdee C

Initiation of transdermal fentanyl among US commercially insured patients between 2007 and 2015

Pain Medicine. 2020 May 7

Costantino RC, Gressler LE, Onukwugha E, McPherson ML, Fudin J, Villalonga-Olives E, Slejko J

Long-term risk of stroke and its predictors in transient ischaemic attack patients in Germany

European Journal of Neurology. 2020 Apr;27(4):723-8

Jacob L, Tanislav C, Kostev K

Reduced antibiotic use after initial treatment of acute respiratory infections with phytopharmaceuticals-a retrospective cohort study

Postgraduate Medicine. 2020 Apr 22:1-7

Martin D, Konrad M, Adarkwah CC, Kostev K

ADVANCING REAL WORLD PATIENT-LEVEL CLINICAL EVIDENCE

Effective diabetes complication management is a step toward a carbon-efficient planet: An economic modeling study

BMJ Open Diabetes Research and Care. 2020 Apr 1;8(1):e001017

Fordham R, Dhatariya K, Stancliffe R, Lloyd A, Chatterjee M, Mathew M, Taneja L, Gains M, Pantou UH

Real-world analysis of switching patients with schizophrenia from oral risperidone or oral paliperidone to once-monthly paliperidone palmitate

Drugs-real world outcomes. 2020 Mar;7(1):19-29

Patel C, Emond B, Lafeuille MH, Côté-Sergent A, Lefebvre P, Tandon N, El Khoury AC

Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosis

Alimentary Pharmacology & Therapeutics. 2020 Mar;51(6):652-60

Moon AM, Jiang Y, Rogal SS, Tapper EB, Lieber SR, Barritt IV AS

Persistence, dose titration, and health care resource utilization among crohn's disease patients treated with ustekinumab: A real-world analysis in the United States

Advances in Therapy. 2020 Mar 19:1-7

Obando C, Ding Z, Muser E, Vaidya N, Qiang W, Sun X, Wang H, Mallampati R, Xie L

Population-based assessment of patient and provider characteristics influencing pediatric outpatient antibiotic use in a high antibiotic-prescribing state

Infection control and hospital epidemiology. 2020 Mar;41(3):331

Katz SE, Staub M, Ouedraogo Y, Evans CD, Kainer MA, Griffin MR, Banerjee R

Real-world adherence in patients with metastatic colorectal cancer treated with trifluridine plus tipiracil or regorafenib

The Oncologist. 2020 Jan;25(1):e75

Patel AK, Barghout V, Yenikomshian MA, Germain G, Jacques P, Laliberté F, Duh MS

Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population

International Journal of Chronic Obstructive Pulmonary Disease. 2019

Bogart M, Stanford RH, Laliberté F, Germain G, Wu JW, Duh MS

Adherence to AED treatment for patients with focal seizure receiving monotherapy with eslicarbazepine acetate or prior generation generics: Evidence from a large US commercial claims database

Neurology, 2019

Mehta D, Lee J, Simeone J, Nordstrom B

Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US

Patient Preference and Adherence. 2019

Guptill JT, Runken MC, Eaddy M, Lunacsek OE,

Fuldeore RM, Blanchette CM, Zacherle E, Noone JM

Longitudinal treatment patterns and adverse events (AEs) in younger patients (Pts) with metastatic triple-negative breast cancer (mTNBC): A real-world landscape analysis

Journal of Clinical Oncology, 2019

Kuderer NM, Varghese D, Hill K, Lyman GH, Botteman M

Epidemiology and real-world treatment of chronic graft-versus-host disease post allogeneic hematopoietic cell transplantation: A US claims analysis

Blood, Vol 134, 2019

Bachier CR, Aggarwal SK, Hennegan K, Milgroom A, Francis K, Rotta M

Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET)

Journal of Clinical Oncology, 2019

Bartlett CH, Mardekian J, Yu-Kite M, Cotter MJ, Kim S,

Decembrino J, Snow T, Carson KR, Motyl Rockland J,

Kraus AL, Wilner KD

ADVANCING REAL WORLD PATIENT-LEVEL CLINICAL EVIDENCE

Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice

BMC Cancer. 2019

Weycker D, Hatfield M, Grossman A, Hanau A, Lonshteyn A, Sharma A, Chandler D

The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first-and second-generation epidermal growth factor receptor tyrosine kinase inhibitors

Lung Cancer. 2019 Dec 1;138:131-8

Subramanian J, Fernandes AW, Laliberté F, Pavilack M, DerSarkissian M, Duh MS

Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study

Arthritis research & therapy. 2019 Dec 1;21(1):228

Simon TA, Boers M, Hochberg M, Baker N, Skovron ML, Ray N, Singhal S, Suissa S, Gomez-Camirero A

Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study

BMC nephrology. 2019 Dec 1;20(1):171

Blankenburg M, Fett AK, Eisenring S, Haas G, Gay A

Real-world utilization of methotrexate or prednisone co-therapy with etanercept among Canadian patients with rheumatoid arthritis: a retrospective cohort study

Current medical research and opinion. 2019 Nov 2;35(11):2025-33

Khraishi M, Ivanovic J, Zhang Y, Millson B, Brabant MJ, Woolcott J, Jones H, Curiale C

Longitudinal, nationwide, cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract infection

Open Forum Infectious Diseases 2019 Nov (Vol. 6, No. 11, p. ofz446). US: Oxford University Press

Carreno JJ, Tam IM, Meyers JL, Esterberg E, Candrilli SD, Lodise Jr TP

Clinical burden of recurrent clostridioides difficile Infection: A real-world data analysis

American Journal of Gastroenterology. 2019 Oct 1;114 (2019 ACG Annual Meeting Abstracts):S95-6

Stong L, Nelson WW, Feuerstadt P, Boules M, Sacks N, Portelli A, Healey B, Lang K, Dahdal DN

Incidence of fractures in young women with breast cancer-a retrospective cohort study

Journal of bone oncology. 2019 Oct 1;18:100254

Stumpf U, Kostev K, Kyvernitakis I, Böcker W, Hadji P

Real-world data approaches for early detection of potential safety and effectiveness signals for generic substitution: a metoprolol extended-release case study

The Journal of Clinical Pharmacology. 2019

Sep;59(9):1275-84

Brown JD, Henriksen C, Vozmediano V, Schmidt S

Period prevalence of chronic pancreatitis diagnosis from 2001–2013 in the commercially insured population of the United States

Pancreatology. 2019 Sep 1;19(6):813-8

Machicado JD, Dudekula A, Tang G, Xu H, Wu BU, Forsmark CE, Yadav D

Medication adherence/persistence and demographics of Japanese dyslipidemia patients on statin-ezetimibe as a separate pill combination pipid-lowering therapy—an observational pharmacy claims database study

Circulation Journal. 2019 Jul 25;83(8):1689-97

Umeda T, Hayashi A, Fujimoto G, Piao Y, Matsui N, Tokita S

Economic and clinical burden of relapsed and/or refractory active treatment episodes in patients with acute myeloid leukemia (AML) in the USA: A retrospective analysis of a commercial payer database

Advances in Therapy. 2019 Jun 20:1-4

Pandya BJ, Chen CC, Medeiros BC, McGuinness CB, Wilson S, Walsh LE, Wade RL

Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States

Diabetes, Obesity and Metabolism. 2019 Jun;21(6):1299-304
Boye KS, Riddle MC, Gerstein HC, Mody R, Garcia-Perez LE, Karanikas CA, Lage MJ, Riesmeyer JS, Lakshmanan MC

Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients

Journal of the American Geriatrics Society. 2019 May 21
Deitelzweig S, Keshishian A, Li X, Kang A, Dhamane AD, Luo X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Nadkarni A

The burden of amputation in patients with peripheral arterial disease (PAD) in the Netherlands

The Journal of cardiovascular surgery. 2019 May 10
Spoorendonk JA, Krol M, Alleman C

Assessment and effect of a gap between new-onset epilepsy diagnosis and treatment in the US

Neurology. 2019 May 7;92(19)
Kalilani L, Faught E, Kim H, Burudpakdee C, Seetasith A, Laranjo S, Friesen D, Haeffs K, Kiri V, Thurman DJ

Treatment patterns and costs of chronic inflammatory demyelinating polyneuropathy: A claims database analysis

American Health & Drug Benefits. 2019 May 1;12(3)
Guptill JT, Runken MC, Eaddy M, Lunacsek O, Fuldeore RM

Real world outpatient treatment patterns of patients with cancer-associated venous thromboembolism in the US

Circulation: Cardiovascular Quality and Outcomes. 2019 Apr;12(Suppl_1)
Guo JD, Hlavacek P, Poretta T, Wygant G, Lane DC, Gorritz M, Wang X, Chen CC, Pan X, Rajpura J, Stwalley B

Outcome evaluation of a subcutaneous immunoglobulin clinical management program

Journal of Research in Pharmacy Practice 2019 Apr;8(2):52
Zhu J, Ayer G, Kirkham HS, Chen CC, Wade RL, Karkare SU, Robson CH, Orange JS

Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States

Human Vaccines & Immunotherapeutics. 2019 Apr 3;15(4):841-9
McLaughlin JM, Swerdlow DL, Khan F, Will O, Curry A, Snow V, Isturiz RE, Jodar L

Comparison of valvulopathy risk with lorcaserin and phenterminetopiramate for weight loss

Current Drug Therapy. 2019 Apr 1;14(1):74-8
Guo M, Etminan M, Carleton B

Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA

Future Oncology. 2019 Mar 19;15(13):1493-504
Lim J, Samuelsen C, Golembesky A, Shrestha S, Wang L, Griebisch I

Calculation of a primary immunodeficiency "Risk Vital Sign" via population-wide analysis of claims data to aid in clinical decision support

Frontiers in pediatrics. 2019 Mar 18;7:70
Rider NL, Miao D, Dodds M, Modell V, Modell F, Quinn J, Schwarzwald H, Orange JS

Evaluation of treatment patterns and costs in patients with prostate cancer and bone metastases

Journal of Managed Care & Specialty Pharmacy. 2019 Mar;25(3-b Suppl):S1-1
Wen L, Yao J, Valderrama A

ADVANCING REAL WORLD PATIENT-LEVEL CLINICAL EVIDENCE

Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans

Current Medical Research and Opinion. 2019 Mar 4;35(3):407-16

Emond B, El Khoury AC, Patel C, Pilon D, Morrison L, Zhdanava M, Lefebvre P, Tandon N, Joshi K

Use of a bioinformatics-based toxicity scoring system to assess serotonin burden and predict population-level adverse drug events from concomitant serotonergic drug therapy

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2019 Feb;39(2):171-81
Culbertson VL, Rahman SE, Bosen GC, Caylor ML, Xu D

Tumor necrosis factor inhibitor therapy and the risk for depression among working-age adults

Oral fluoroquinolones and risk of fibromyalgia
British journal of Clinical Pharmacology. 2019 Jan;85(1):236-9

Ganjizadeh-Zavareh S, Sodhi M, Spangehl T, Carleton B, Etminan M

A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies

PloS one. 2019 Jan 14;14(1):e0210417

Duquette P, Yeung M, Mouallif S, Nakhaipour HR, Haddad P, Schechter R

Comparison of drug switching and discontinuation rates in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants in the United States

Advances in Therapy. 2019 Jan 1;36(1):162-74

Baker CL, Dhamane AD, Mardekian J, Dina O, Russ C, Rosenblatt L, Lingohr-Smith M, Menges B, Lin J, Nadkarni A

About the Institute



The IQVIA Institute for Human Data Science contributes to the advancement of human health globally through timely research, insightful analysis and scientific expertise applied to granular non-identified patient-level data.

Fulfilling an essential need within healthcare, the Institute delivers objective, relevant insights and research that accelerate understanding and innovation critical to sound decision making and improved human outcomes. With access to IQVIA's institutional knowledge, advanced analytics, technology and unparalleled data the Institute works in tandem with a broad set of healthcare stakeholders to drive a research agenda focused on Human Data Science including government agencies, academic institutions, the life sciences industry and payers.

Research Agenda


The research agenda for the Institute centers on 5 areas considered vital to contributing to the advancement of human health globally:

- Improving decision-making across health systems through the effective use of advanced analytics and methodologies applied to timely, relevant data.
- Addressing opportunities to improve clinical development productivity focused on innovative treatments that advance healthcare globally.
- Optimizing the performance of health systems by focusing on patient centricity, precision medicine and better understanding disease causes, treatment consequences and measures to improve quality and cost of healthcare delivered to patients.
- Understanding the future role for biopharmaceuticals in human health, market dynamics, and implications for manufacturers, public and private payers, providers, patients, pharmacists and distributors.
- Researching the role of technology in health system products, processes and delivery systems and the business and policy systems that drive innovation.

Guiding Principles

The Institute operates from a set of guiding principles:

- Healthcare solutions of the future require fact based scientific evidence, expert analysis of information, technology, ingenuity and a focus on individuals.
- Rigorous analysis must be applied to vast amounts of timely, high quality and relevant data to provide value and move healthcare forward.
- Collaboration across all stakeholders in the public and private sectors is critical to advancing healthcare solutions.
- Insights gained from information and analysis should be made widely available to healthcare stakeholders.
- Protecting individual privacy is essential, so research will be based on the use of non-identified patient information and provider information will be aggregated.
- Information will be used responsibly to advance research, inform discourse, achieve better healthcare and improve the health of all people.



The IQVIA Institute for Human Data Science is committed to using human data science to provide timely, fact-based perspectives on the dynamics of health systems and human health around the world. The cover artwork is a visual representation of this mission. Using algorithms and data from the report itself, the final image presents a new perspective on the complexity, beauty and mathematics of human data science and the insights within the pages.

Artwork on the cover of this document was generated using data about per capita antibiotic use and the number of antibiotic prescriptions written in the U.S. in 2017 and 2018.



CONTACT US

100 IMS Drive
Parsippany, NJ 07054
United States
info@iqviainstitute.org
iqviainstitute.org